PROBIOTICS IN A PRE- AND/OR POST SURGICAL ENVIRONMENT
    3.
    发明申请
    PROBIOTICS IN A PRE- AND/OR POST SURGICAL ENVIRONMENT 有权
    预防和/或手术后环境中的生物技术

    公开(公告)号:US20100135971A1

    公开(公告)日:2010-06-03

    申请号:US12598905

    申请日:2008-05-14

    申请人: Eduardo Schiffrin

    发明人: Eduardo Schiffrin

    IPC分类号: A61K45/00 A61P1/14

    摘要: The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment.

    摘要翻译: 本发明一般涉及营养领域,更具体地涉及益生菌在营养中的应用。 特别地,本发明涉及益生菌或益生菌混合物在制造营养组合物或药物中在手术前或手术后环境中作用的用途。

    Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis
    6.
    发明申请
    Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis 有权
    用于治疗和/或预防贾第虫病的乳酸菌

    公开(公告)号:US20050186191A1

    公开(公告)日:2005-08-25

    申请号:US11111255

    申请日:2005-04-20

    摘要: The present invention relates to the use of a supernatant of lactic acid bacteria or of Bifidobacteria capable of preventing colonization of intestinal cells by Giardia intestinalis, for the preparation of an ingestible carrier for the treatment and/or prophylaxis of disorders associated with the colonization of the gut by Giardia intestinalis. The present invention also pertains to specific strains of Bifidobacterium having the above traits and to the ingestible carrier, such as a food or pharmaceutical composition, containing such supernatant or the microorganisms.

    摘要翻译: 本发明涉及乳酸菌或双歧杆菌的上清液的用途,所述双歧杆菌能够预防肠梗阻引起的肠细胞的定殖,用于制备可摄取的载体,用于治疗和/或预防与 肠道由贾第鞭毛虫肠道 本发明还涉及具有上述性状的双歧杆菌和含有这种上清液或微生物的可摄入载体,例如食品或药物组合物的具体菌株。

    Probiotics in a pre- and/or post surgical environment
    7.
    发明授权
    Probiotics in a pre- and/or post surgical environment 有权
    前和/或后手术环境中的益生菌

    公开(公告)号:US08529887B2

    公开(公告)日:2013-09-10

    申请号:US12598905

    申请日:2008-05-14

    申请人: Eduardo Schiffrin

    发明人: Eduardo Schiffrin

    IPC分类号: A01N63/00 C12N1/20

    摘要: The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment.

    摘要翻译: 本发明一般涉及营养领域,更具体地涉及益生菌在营养中的应用。 特别地,本发明涉及益生菌或益生菌混合物在制造营养组合物或药物中在手术前或手术后环境中作用的用途。

    ENDOTOXIN BINDING BY LACTIC ACID BACTERIA AND BIFIDOBACTERIA
    9.
    发明申请
    ENDOTOXIN BINDING BY LACTIC ACID BACTERIA AND BIFIDOBACTERIA 有权
    内毒素结合酸性细菌和双歧杆菌

    公开(公告)号:US20100136662A1

    公开(公告)日:2010-06-03

    申请号:US12488293

    申请日:2009-06-19

    IPC分类号: C12N1/20

    摘要: The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof

    摘要翻译: 本发明涉及至少一种具有疏水表面性质的乳酸菌和/或双歧杆菌菌株在制备用于预防或治疗内毒素介导和/或相关疾病和人或宠物食物的组合物中的用途 其制备的组合物

    Treatment of Stressed Patients
    10.
    发明申请
    Treatment of Stressed Patients 审中-公开
    治疗重症患者

    公开(公告)号:US20090011077A1

    公开(公告)日:2009-01-08

    申请号:US12097847

    申请日:2007-01-04

    IPC分类号: A23L1/29 A23L1/305

    摘要: Methods and compositions for providing nutrition to critically ill patients are presented. In an embodiment, the method comprises administering to a patient undergoing a condition characterized bya systemic inflammatory response phase followed by a compensatory anti-inflammatory response phase a first nutritional composition while the patient is experiencing the first phase and administering to the patient a second different nutritional composition while the patient is experiencing the second phase.

    摘要翻译: 介绍了向危重病人提供营养的方法和组成。 在一个实施方案中,所述方法包括在患者经历第一阶段并且向患者施用第二种不同营养物质的情况下,对患有经历系统性炎症反应阶段的特征的患者施用第一营养组合物,然后补偿性抗炎反应阶段的第一营养组合物 而患者正在经历第二阶段。